Competing Priorities: Alzheimer's Drugs and the Delicate Balance that Defines Part D

The Alzheimer’s Association waged and won a six-month battle to end prior authorization programs for AD medications in three Medicare plans. The skirmish has big implications for future of Medicare formularies— and the balance of power between Big Pharma and managed care.

By Michael McCaughan

"Caremark is stubborn." That was the conclusion of Leslie Fried, an American Bar Association attorney who is working with the...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet